RT @ATRIUMRx: HFpEF is a heterogeneous disorder but could response to therapy differ even by sex? A recent post hoc analysis of TOPCAT in @…
@AndreasGevaert @lamcardio @JACCJournals @AnastasiaSMihai @krychtiukmd @DrMarthaGulati @GiuseppeGalati_ @SilCastelletti @SABOURETCardio @ShelleyZieroth @purviparwani @I_Witvrouwen See also https://t.co/U1gPDkpkAc in the same issue of the journal! https://t
RT @JACCJournals: Do women with #HFpEF respond better to spironolactone than men? See the TOPCAT analysis in #JACCHF. https://t.co/7tvq7ZEe…
RT @JACCJournals: Do women with #HFpEF respond better to spironolactone than men? See the TOPCAT analysis in #JACCHF. https://t.co/7tvq7ZEe…
RT @JACCJournals: Do women with #HFpEF respond better to spironolactone than men? See the TOPCAT analysis in #JACCHF. https://t.co/7tvq7ZEe…
RT @JACCJournals: Do women with #HFpEF respond better to spironolactone than men? See the TOPCAT analysis in #JACCHF. https://t.co/7tvq7ZEe…
RT @hilariobad59: @JACCJournals TOPCAT mostró reducción en la mortalidad por todas las causas asociada con el tratamiento con espironolacto…
@JACCJournals TOPCAT mostró reducción en la mortalidad por todas las causas asociada con el tratamiento con espironolactona en mujeres Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction https://t.c
RT @JACCJournals: Do women with #HFpEF respond better to spironolactone than men? See the TOPCAT analysis in #JACCHF. https://t.co/7tvq7ZEe…
RT @JACCJournals: Do women with #HFpEF respond better to spironolactone than men? See the TOPCAT analysis in #JACCHF. https://t.co/7tvq7ZEe…
RT @JACCJournals: Do women with #HFpEF respond better to spironolactone than men? See the TOPCAT analysis in #JACCHF. https://t.co/7tvq7ZEe…
RT @JACCJournals: Do women with #HFpEF respond better to spironolactone than men? See the TOPCAT analysis in #JACCHF. https://t.co/7tvq7ZEe…
Saving this to read later! Sex interaction with spironolactone in women with HFpEF?
Do women with #HFpEF respond better to spironolactone than men? See the TOPCAT analysis in #JACCHF. https://t.co/7tvq7ZEeZf @LindenfeldJoann @DrNancySweitzer https://t.co/TTOcYCTWRZ
RT @ATRIUMRx: HFpEF is a heterogeneous disorder but could response to therapy differ even by sex? A recent post hoc analysis of TOPCAT in @…
HFpEF is a heterogeneous disorder but could response to therapy differ even by sex? A recent post hoc analysis of TOPCAT in @JCardFail suggests it's possible: https://t.co/3oSkKglei6 #CardioEd
Another "exploratory" posthoc subgroup analysis of TOPCAT: https://t.co/2lD93s79bS. Can we just re-do the trial in North American women with HFpEF? Hey #cardprn, should we start a Kickstarter campaign?
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @hect2701: @hect2701 #CRT2019 @SelmaFMohammed and cols will present this weekend at #CRT their experience treating advance heart failure…
@hect2701 #CRT2019 @SelmaFMohammed and cols will present this weekend at #CRT their experience treating advance heart failure patients... CRT is much more than a cardiac device meeting
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @coconnormd: Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction | JACC: Heart…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
Good paper showing possible further spironolactone benefit in women with HFpEF. Not addressed is role of baseline EF, since in TOPCAT, most benefit overall went to those with lower EF <50%, so not true HFpEF. https://t.co/iCkDGq2lEI
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @coconnormd: Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction | JACC: Heart…
Interesting post-hoc analysis of TOPCAT analysing gender based response to Spironolactone to HFPEF. Needs prospective randomised study but reinforces opinion the GDMT for #heartfailure effects are different in women https://t.co/zRrNG0E2EJ
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
RT @paomorejon: 📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #…
📌Diferencias👩🏻🧔🏻en la respuesta a espironolactona •Subanálisis del TOPCAT •👩🏻Menos comorbilidades pero; peores resultados #InsuficienciaCardiaca con fey preservada🙋🏻♀️nos beneficiamos de espironolactona. ⚠️Reducir tratamientos sin evidencia⁉️ https://t.co
RT @coconnormd: Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction | JACC: Heart…
Vast majority of HFpEF pts are still on diuretics and beta blockers...with little to no evidence. Let’s get our patients on aldactone. GDMT IN HFpEF. #whateverittakes.
RT @coconnormd: Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction | JACC: Heart…
RT @coconnormd: Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction | JACC: Heart…
RT @coconnormd: Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction | JACC: Heart…
RT @coconnormd: Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction | JACC: Heart…
RT @coconnormd: Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction | JACC: Heart…
Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction | JACC: Heart Failure: Is MRA therapy more efficacious in women than men? https://t.co/30QNFI513w
RT @AnastasiaSMihai: Sex Differences in Outcomes & Responses to Spironolactone in HFpEF https://t.co/hsfRdEQiWb Post-hoc analysis of TOPCA…
Sex Differences in Outcomes & Responses to Spironolactone in HFpEF https://t.co/hsfRdEQiWb Post-hoc analysis of TOPCAT: ➡ 49.9%💃(highest proportion of all MRA HF trials) ➡ no differences in 1 outcome ➡Spiro associated with reduced all-cause mortality